根治的前立腺切除術の候補である高リスク、限局性または局所進行性前立腺癌の参加者におけるアパルタミドの研究 (PROTEUS)
根治的前立腺切除術の候補である高リスク、限局性または局所進行性前立腺癌の被験者におけるアパルタミドの無作為化二重盲検プラセボ対照第III相試験
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
Los Angeles、California、アメリカ、90033
- University of Southern California
-
Los Angeles、California、アメリカ、90095
- University of California Los Angeles
-
Los Angeles、California、アメリカ、90048
- Cedars Sinai Medical Center
-
Orange、California、アメリカ、92868
- University of California Irvine Medical Center Chao Family Comprehensive Cancer Center
-
Sacramento、California、アメリカ、95817
- UC Davis Medical Center
-
-
Colorado
-
Denver、Colorado、アメリカ、80210
- AdventHealth Medical Group Urology of Denver
-
Lakewood、Colorado、アメリカ、80228
- Colorado Clinical Research
-
-
Connecticut
-
Stamford、Connecticut、アメリカ、06904
- Stamford Hospital
-
-
Florida
-
Hialeah、Florida、アメリカ、33002
- Urology Specialists LLC
-
Jacksonville、Florida、アメリカ、32224
- Mayo Clinic - Division Of Hematology/oncology
-
Miami、Florida、アメリカ、33176
- Miami Cancer Institute at Baptist Health / Baptist Health Medical Group
-
Orlando、Florida、アメリカ、32804
- Advent Health
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322-1013
- Emory University Winship Cancer Institute
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago
-
-
Louisiana
-
Shreveport、Louisiana、アメリカ、71106
- Ochsner LSU Health Shreveport - Regional Urology
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Dana Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02215
- Beth Isreal Deaconess Medical Center
-
-
Michigan
-
Troy、Michigan、アメリカ、48084
- Michigan Institute of Urology, PC
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Saint Louis University
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- Urology Cancer Center, PC
-
-
New York
-
Albany、New York、アメリカ、12208
- Albany Medical College
-
Cheektowaga、New York、アメリカ、14225
- Great Lakes Physician PC d/b/a Western New York Urology Associates
-
New York、New York、アメリカ、10065
- Weill Cornell Medical College
-
New York、New York、アメリカ、10065
- Memorial Sloan-Kettering Cancer Center
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina
-
Durham、North Carolina、アメリカ、27705
- Duke University School of Medicine
-
Greensboro、North Carolina、アメリカ、27403
- Medication Management LLC
-
Huntersville、North Carolina、アメリカ、28078
- Carolina Urology Partners, PLLC
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- Cleveland VA Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- Oklahoma City VAMC
-
-
Pennsylvania
-
Bala-Cynwyd、Pennsylvania、アメリカ、19004
- MidLantic Urology
-
-
Rhode Island
-
Warwick、Rhode Island、アメリカ、02886
- Omega Medical Research
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29403
- Medical University of South Carolina
-
Charleston、South Carolina、アメリカ、29401
- Ralph H. Johnson Veterans Affairs Medical Center
-
Greenville、South Carolina、アメリカ、29605
- Greenville Health
-
Myrtle Beach、South Carolina、アメリカ、29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas、Texas、アメリカ、75216
- VA North Texas Health Care System
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center
-
-
Virginia
-
Richmond、Virginia、アメリカ、23235
- Virginia Urology
-
Virginia Beach、Virginia、アメリカ、23462
- Urology of Virginia, PLCC
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- CAMC Memorial Hospital, Charleston Area Medical Center Physicians
-
-
-
-
-
Caba、アルゼンチン、1118
- Hospital Aleman
-
Ciudad Autonoma de、アルゼンチン、C1199ABB
- Hospital Italiano de Buenos Aires
-
Córdoba、アルゼンチン、X5000KPH
- Centro Urologico Profesor Bengio
-
Córdoba、アルゼンチン、X5008AAC
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Mendoza、アルゼンチン、5500
- Uroclinica
-
San Miguel de Tucumán、アルゼンチン、4000
- Clinica Mayo de UMCB
-
-
-
-
-
Bristol、イギリス、BS10 5NB
- Southmead Hospital
-
Cardiff、イギリス、CF14 4XW
- University Hospital of Wales
-
Dundee、イギリス、DD2 1UB
- Ninewells Hospital
-
London、イギリス、WC1E 6BT
- University College London
-
London、イギリス、SW3 6JJ
- The Royal Marsden NHS Trust
-
Preston、イギリス、PR2 9HT
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
Sutton、イギリス、SM2 5PT
- Royal Marsden Hospital
-
Wakefield、イギリス、WF1 4DG
- Mid Yorkshire NHS Trust
-
Wolverhampton、イギリス、WV10 0QP
- New Cross Hospital
-
-
-
-
-
Beer Yaakov、イスラエル、60930
- Asaf Harofe Medical Center
-
Haifa、イスラエル、31096
- Rambam Health Care Campus
-
Kfar Saba、イスラエル、4428164
- Tel Aviv University Sackler School of Medicine - Meir Medical Center (MMC)
-
Petah Tikva、イスラエル、49100
- Rabin Medical Center
-
Ramat Gan、イスラエル、52621
- The Chaim Sheba Medical Center
-
Tel Aviv、イスラエル、64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Abano Terme、イタリア、35031
- Policlinico Abano Terme
-
Acquaviva delle Fonti、イタリア、70021
- Generale Regionale F. Miulli
-
Bassano del Grappa、イタリア、36061
- Ospedale di Bassano del Grappa
-
Brescia、イタリア、25123
- ASST Spedali Civili Brescia
-
Chieti、イタリア、66100
- ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti
-
Florence、イタリア、50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan、イタリア、20132
- Ospedale San Raffaele
-
Milan、イタリア、20141
- Istituto Europeo di Oncologia
-
Milan、イタリア、20127
- San Raffaele Turro - Istituto di Ricovero e Cura a Carattere Scientifico
-
Modena、イタリア、41100
- Clinica di Urologia Policlinico di Modena - Universita di Modena e reggio Emilia
-
Novara、イタリア、28100
- Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara
-
Orbassano、イタリア、10043
- Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga
-
Roma、イタリア、00144
- Istituto Nazionale Tumori Regina Elena
-
Roma、イタリア、00189
- Azienda Ospedaliera Sant Andrea
-
Roma、イタリア、00128
- Universita Campus Bio-Medico di Roma
-
Torino、イタリア、10126
- Ospedale Molinette, AO Città della Salute e della Scienza di
-
Verona、イタリア、37126
- UOC di Urologia AOU Integrata di Verona - Polo Chirurgico Confortini - Ospedale Borgo Trento
-
-
-
-
-
Amsterdam、オランダ、1066 CX
- Antoni van Leeuwenhoek
-
Eindhoven、オランダ、5623 EJ
- Catharinaziekenhuis
-
Nieuwegein、オランダ、3430EM
- St. Antonius Ziekenhuis (St. Antonius Hospital)
-
Nijmegen、オランダ、6524 KD
- Canisius-Wilhelmina Ziekenhuis
-
-
-
-
-
Box Hill、オーストラリア、3128q
- Eastern Health - Box Hill Hospital
-
Darlinghurst、オーストラリア、2010
- St Vincent s Hospital Sydney
-
Heidelberg、オーストラリア、3084
- Austin Health
-
Malvern、オーストラリア、3144
- Australian Urology Associates Pty Ltd
-
Parkville、オーストラリア、3052
- Royal Melbourne Hospital
-
St Leonards、オーストラリア、2065
- Northern Cancer Institute
-
Wahroonga、オーストラリア、2076
- Sydney Adventist Hospital
-
Westmead、オーストラリア、2145
- Westmead Hospital
-
Woolloongabba、オーストラリア、4102
- Princess Alexandra Hospital
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2V 1P9
- Prostate Cancer Centre
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1M9
- Vancouver Prostate Centre, Gordon and Leslie Diamond Health Care Centre
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- London Health Sciences Center
-
Toronto、Ontario、カナダ、M5G2M9
- Princess Margaret Cancer Centre University Health Network
-
Toronto、Ontario、カナダ、M4N 3M5
- Sunnybrook Health Sciences Center
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 0A9
- CHUM - Centre hospitalier universitaire de Montreal
-
Québec、Quebec、カナダ、G1R 2J6
- CHU de Quebec Universite Laval Hopital de l Enfant Jesus
-
-
-
-
-
A Coruña、スペイン、15006
- Hosp Univ A Coruna
-
Barcelona、スペイン、8035
- Hosp Univ Vall D Hebron
-
Cadiz、スペイン、11009
- Hosp. Puerta Del Mar
-
Castellon、スペイン、12004
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera、スペイン、11407
- Hosp. de Jerez de La Frontera
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28046
- Hosp. Univ. La Paz
-
Manacor、スペイン、07500
- Fund. Hosp. de Manacor
-
Málaga、スペイン、29010
- Hosp Virgen de La Victoria
-
Santander、スペイン、39008
- Hosp. Univ. Marques de Valdecilla
-
Seville、スペイン、41013
- Hosp. Virgen Del Rocio
-
Valencia、スペイン、46009
- Inst. Valenciano de Oncologia
-
Valencia、スペイン、46010
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Hradec Králove、チェコ、500 05
- Fakultni nemocnice Hradec Kralove
-
Liberec、チェコ、460 63
- Krajská nemocnice Liberec
-
Olomouc、チェコ、77200
- Uromedical Center s.r.o.
-
Pilsen、チェコ、305 99
- Fakultni nemocnice Plzen, Urologicka klinika
-
Prague、チェコ、140 59
- Thomayerova nemocnice
-
Prague、チェコ、120 00
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Aachen、ドイツ、52074
- Universitaetsklinikum der RWTH Aachen
-
Braunschweig、ドイツ、38126
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne、ドイツ、50937
- Universitaetsklinikum Koelnt
-
Eisleben Lutherstadt、ドイツ、06295
- Praxis Dr. med. Ralf Eckert
-
Essen、ドイツ、45147
- Universitatsklinikum Essen
-
Frankfurt am Main、ドイツ、60590
- Universitatsklinikum Frankfurt
-
Gronau、ドイツ、48599
- Prostata zentrum Nordwest
-
Hamburg、ドイツ、20246
- Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
-
Homburg/Saar、ドイツ、66421
- Universitätsklinikum des Saarlandes
-
Lübeck、ドイツ、23538
- Universitatsklinikum Schleswig Holstein Campus Lubeck
-
Straubing、ドイツ、94315
- Klinikum St. Elisabeth Straubing GmbH
-
Weiden/Opf、ドイツ、92637
- Kliniken Nordoberpfalz, Klinik für Urologie
-
Wilhelmshaven、ドイツ、26389
- Praxisgemeinschaft f. Onkologie u. Urologie - Germany
-
-
-
-
-
Angers、フランス、49933
- CHU d'Angers
-
Besançon、フランス、25030
- CHRU Besancon Hopital Jean Minjoz
-
Bordeaux、フランス、33076
- Hopital Pellegrin CHU Bordeaux
-
Créteil、フランス、94010
- APHP - Hopital Henri Mondor
-
Lyon、フランス、69437
- Hopital Edouard Herriot - CHU Lyon
-
Nantes、フランス、44000
- CHU de Nantes hotel Dieu
-
Paris、フランス、75014
- Institut Mutualiste Montsouris
-
Quint-Fonsegrives、フランス、31130
- Clinique de la Croix du Sud
-
Rennes、フランス、35033
- Chu Rennes Hopital Pontchaillou
-
Toulouse、フランス、31059
- CHU de Toulouse - Hôpital Rangueil
-
Tours、フランス、37000
- CHRU Tours Hopital Bretonneau
-
-
-
-
-
Goiânia、ブラジル、74605-070
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
-
Ijuí、ブラジル、98700-000
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
-
Natal、ブラジル、59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、ブラジル、90020-090
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Rio de Janeiro、ブラジル、20551-030
- Universidade do Estado do Rio de Janeiro - UERJ
-
São Paulo、ブラジル、01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo、ブラジル、01243 020
- Hospital Samaritano de Sao Paulo
-
Três Lagoas、ブラジル、79601-001
- Instituto Do Cancer Brasil
-
-
-
-
-
Bydgoszcz、ポーランド、85 094
- Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza
-
Bydgoszcz、ポーランド、85 015
- Samodzielny Publiczny Wielospecjalistyczny Zaklad Opieki Zdrowotnej Mswia W Bydgoszczy
-
Koszalin、ポーランド、75 581
- Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
-
Krakow、ポーランド、30-727
- Pratia MCM Krakow
-
Warsaw、ポーランド、02-473
- City Clinic Sp. z o.o.
-
Wroclaw、ポーランド、53-413
- Dolnoslaskie Centrum Onkologii, Oddzial Chirurgii Onkologicznej II - Urologia
-
-
-
-
-
Barnaul、ロシア、656049
- Altai Regional Oncology Dispensary
-
Chelyabinsk、ロシア、454087
- Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
-
Moscow、ロシア、125284
- Hertzen Oncology Research Institute
-
Moscow、ロシア、121205
- Moscow City Oncology Hospital No 62
-
Omsk、ロシア、644013
- Clinical Oncology Dispensary
-
Tyumen、ロシア、625000
- Medical-sanitary unit 'Neftyanik'
-
Vologda、ロシア、160012
- Vologda Regional Oncological Dispensary
-
-
-
-
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung、台湾、40447
- China Medical University Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Taichung、台湾、435
- Tungs' Taichung MetroHarbor Hospital
-
Tainan、台湾、710
- Chi Mei Medical Center Yong Kang
-
Taipei、台湾、10002
- National Taiwan University Hospital
-
-
-
-
-
Akita、日本、010-8543
- Akita University Hospital
-
Chiba、日本、260 8677
- Chiba University Hospital
-
Chūōku、日本、260-8717
- Chiba Cancer Center
-
Hakodate、日本、040 8611
- Hakodate Goryoukaku Hospital
-
Hirosaki、日本、036-8203
- Hirosaki University Hospital
-
Kanazawa、日本、920 8641
- Kanazawa University Hospital
-
Kobe、日本、650-0047
- Kobe City Medical Center General Hospital
-
Koshigaya、日本、343-8555
- Dokkyo Medical University Saitama Medical Center
-
Kurume、日本、830-0011
- Kurume University Hospital
-
Kyoto、日本、606-8507
- Kyoto University Hospital
-
Matsuyama、日本、791-0280
- National Hospital Organization Shikoku Cancer Center
-
Minamiku、日本、252-0375
- Kitasato University Hospital
-
Miyazaki、日本、889-1692
- University of Miyazaki Hospital
-
Nagano、日本、381-8551
- Nagano Municipal Hospital
-
Osaka、日本、541 8567
- Osaka International Cancer Institute
-
Sakai、日本、590 0197
- Kindai University Hospital
-
Sakura、日本、285-8741
- Toho University Sakura Medical Center
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Shiwa-gun、日本、028-3695
- Iwate Medical University Hospital
-
Tokyo、日本、113-8421
- Juntendo University Hospital
-
Tokyo、日本、113 8603
- Nippon Medical School Hospital
-
Ube、日本、755-8505
- Yamaguchi University Hospital
-
Yokohama、日本、232 0024
- Yokohama City University Medical Center
-
-
-
-
-
Gwangju、韓国、61469
- Chonnam National University Hospital
-
Gyeonggi-do、韓国、13605
- Seoul National University Bundang Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06591
- The Catholic University of Korea Seoul St Marys Hospital
-
Seoul、韓国、05505
- Asan Medical Center 1
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate
- High-risk disease defined by a total Gleason Sum Score greater than equal to (>=) 4+3 (=Grade Groups [GG] 3-5) and >=1 of the following 4 criteria: a) Any combination of Gleason Score 4+3 (= 3) and Gleason Score 8 (4+4 or 5+3) in >= 6 systematic cores (with >=1 core Gleason Score 8 [4+4 or 5+3] included); b) Any combination of Gleason Score 4+3 (=GG 3) and Gleason Score 8 (4+4 or 5+3) in >=3 systematic cores and Prostate-specific antigen (PSA) >=20 ng/mL (with >= 1 core Gleason Score 8 [4+4 or 5+3] included); c) Gleason Score >=9 (=GG 5) in at least 1 systematic or targeted core; d) At least 2 systematic or targeted cores with continuous Gleason Score >=8 (=GG 4), each with > 80 percent (%) involvement
- Candidate for radical prostatectomy with pelvic lymph node dissection as per the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Contraceptive use by male participants (and female partners of male participants enrolled in the study who are of childbearing potential or are pregnant) should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies
- Able to receive androgen deprivation therapy (ADT) for at least 13 months
Exclusion Criteria:
- Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Participants are considered eligible only if the central radiological review confirms clinical stage M0
- (a) Prior treatment with androgen receptor antagonists; (b) Treatment with gonadotropin-releasing hormone analog (GnRHa) prior to informed consent form (ICF) signature
- History of prior systemic or local therapy for prostate cancer, including pelvic radiation for prostate cancer
- Use of any investigational agent less than or equals to (<=)4 weeks prior to randomization or any therapeutic procedure for prostate cancer at any time
- Major surgery <=4 weeks prior to randomization
- Any of the following within 12 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (example, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated deep vein thrombosis is not considered exclusionary
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Apalutamide + ADT
Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment. A Long-Term Extension (LTE) may be initiated at sponsor's discretion after completion of the primary endpoint analysis. |
Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
他の名前:
Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter [ng/dL]). |
|
実験的:Placebo + ADT
Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment. A LTE may be initiated at sponsor's discretion after completion of the primary endpoint analysis. |
Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter [ng/dL]). Participants will receive matching placebo oral tablets daily. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Pathologic complete response (pCR)
時間枠:Approximately 4 years
|
pCR is assessed by a pathology blinded independent central radiology review (BICR) as defined in the pathology charter. |
Approximately 4 years
|
|
Metastasis-Free Survival (MFS)
時間枠:Up to 7 years and 5 months
|
MFS is defined as the time from randomization to the date of the occurrence of radiographic distant metastasis evaluated by radiology BICR, incidental pathologic finding of distant metastasis, or death from any cause, whichever occurs first. |
Up to 7 years and 5 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Prostate Specific Antigen (PSA)-Free Survival
時間枠:Approximately 4 years
|
PSA-free survival with testosterone recovery defined as the time from randomization to the first detectable serum PSA level with recovered testosterone levels after undetectable PSA post-radical prostatectomy with pelvic lymph node dissection or death, whichever occurs first. |
Approximately 4 years
|
|
Event Free Survival (EFS)
時間枠:Up to 7 years and 5 months
|
EFS defined as time from randomization to any of the following events: biochemical failure (BCF); or local or regional recurrence by BICR or histopathological assessment; or distant metastasis by BICR or histopathological assessment; or death. |
Up to 7 years and 5 months
|
|
Time to Subsequent First Treatments (TTST-1)
時間枠:Up to 7 years and 5 months
|
TTST-1 is defined as the time from randomization to the date of first subsequent therapy. |
Up to 7 years and 5 months
|
|
Time to Distant Metastasis (TTDM)
時間枠:Up to 7 years and 5 months
|
TTDM is defined as the time from the date of enrollment until the first date of distant metastasis. |
Up to 7 years and 5 months
|
|
MFS Based on Conventional Imaging
時間枠:Up to 7 years and 5 months
|
MFS based on conventional imaging, defined as the time from randomization to the date of the first occurrence of radiographic distant metastasis on CT/MRI and bone scan by radiology BICR, pathologic finding of distant metastasis, or death from any cause, whichever occurs first. |
Up to 7 years and 5 months
|
|
Number of Participants with No Evidence of Disease (NED) at 4 Years
時間枠:Up to 4 years
|
Number of participants with NED at 4 years will be reported. NED at 4 years is defined as: (a) alive, (b) Undetectable prostate-specific antigen (PSA), (c) No distant metastasis, (d) No local or regional recurrence, (e) No subsequent therapy for prostate cancer, (f) Testosterone recovery to physiological testosterone levels, defined as 200 nanograms per deciliter (ng/dL). |
Up to 4 years
|
|
Number of Participants with Vital Signs Abnormalities as a Measure of Safety and Tolerability
時間枠:Up to 30 days after last dose of study drug (Approximately 8 years)
|
Number of participants with vital signs (including body temperature, heart rate, respiratory rate, and blood pressure) abnormalities will be reported. |
Up to 30 days after last dose of study drug (Approximately 8 years)
|
|
Number of Participants with Physical Examinations Abnormalities as a Measure of Safety and Tolerability
時間枠:Up to 30 days after last dose of study drug (Approximately 8 years)
|
Number of participants with physical examinations (including general appearance of the participant, height, weight, and examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system) abnormalities will be reported. |
Up to 30 days after last dose of study drug (Approximately 8 years)
|
|
Number of Participants with Laboratory Abnormalities as a Measure of Safety and Tolerability
時間枠:Up to 30 days after last dose of study drug (Approximately 8 years)
|
Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing. |
Up to 30 days after last dose of study drug (Approximately 8 years)
|
|
Number of Participants with Treatment Compliance Rate
時間枠:Up to 30 days after last dose of study drug (Approximately 8 years)
|
Number of participants who are complaint with study treatment will be assessed. |
Up to 30 days after last dose of study drug (Approximately 8 years)
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
一般刊行物
- Ravi P, Kwak L, Xie W, Kelleher K, Acosta AM, McKay RR, Kibel AS, Taplin ME. Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. J Urol. 2022 Oct;208(4):838-845. doi: 10.1097/JU.0000000000002803. Epub 2022 Sep 9.
- Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damiao R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juarez Soto A, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS; PROTEUS Investigators. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med. 2026 Aug 6;395(6):546-560. doi: 10.1056/NEJMoa2603878. Epub 2026 May 31.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR108535
- 2018 (米国 NIH グラント/契約)
- 56021927PCR3011 (その他の識別子:Janssen Research & Development, LLC)
- 2018-001746-34 (EudraCT番号)
- 2023-506153-38-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。